skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.12d (Release date: 2017-12-26)
SearchBox Top
SearchBox Bottom
HLA-A*2402-Restricted CDCA1-KIF20A Multipeptide Vaccine (Code C90568)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: HLA-A*2402-Restricted CDCA1-KIF20A Multipeptide Vaccine

Definition: A cancer vaccine containing two HLA-A*2402-restricted peptide epitopes derived from cancer-testis antigens with potential immunostimulatory and antitumor activities. The peptide epitopes are derived from cell division associated 1 (CDCA1) and kinesin-like family member 20A (KIF20A). Upon administration, HLA-A*2402-restricted CDCA1-KIF20A multipeptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against CDCA1- and KIF20A-expressing tumor cells, resulting in tumor cell lysis and decreased tumor cell proliferation. HLA-A*2402 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A*2402 may improve antigenic peptide immunogenicity.

Label: HLA-A*2402-Restricted CDCA1-KIF20A Multipeptide Vaccine

NCI Thesaurus Code: C90568 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: CL416252  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
HLA-A*2402-Restricted CDCA1-KIF20A Multipeptide Vaccine

External Source Codes: 
PDQ Closed Trial Search ID 667431
PDQ Open Trial Search ID 667431 (check for NCI PDQ open clinical trial info)

Other Properties:
     Name Value (qualifiers indented underneath)
code C90568
Semantic_Type Immunologic Factor
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom